Company portrait
ARTIFICIAL INTELLIGENCE IN DIAGNOSTICS - REAL INNVATION IN ALLERGY TESTING
MILTON ESSEX SA is a med-tech public company listed on the NewConnect Market of the Warsaw Stock Exchange, which specializes in development of advanced medical imaging systems equipped with Artificial Intelligence dedicated for automated noninvasive diagnostics of skin tissue on basis of multispectral scanning (including far infrared spectrum). We implement infrared imaging technology thanks to close engineering cooperation in a frame of a joint research Consortium "FOTONICA" with the Institute of Optoelectronics of the Military University of Technology - a leading European center for laser & optronics technology. Intelligent digital systems for multispectral hybrid imaging are extremely complex diagnostic tools which place MILTON ESSEX SA in the world's premier league of med-equipment manufacturers focusing on skin diseases/allergies.
Automation of allergy diagnostics
The basic instruments that support the physician in the daily diagnosis of skin diseases have basically remained unchanged for more than 70 years. They are almost without exception based on optical technique, i.e. a more or less precise magnifying glass that allows viewing lesions in visible light at high magnification.Only in recent years, optical dermatoscopy has been supported by computer image analysis, allowing further comparison with other cases collected in digital libraries. However, the best computer systems cannot overcome the barrier of relying in skin diagnostics on symptomatology, i.e. assessment of morphology of the examined lesion in visible light (based on shape, pigmentation, contour, etc.). Such approach, which is focusing only on the epidermally visible symptoms rather on scientifically proven markers, cannot be longer accepted due to requirements of EBM (Evidence-Based Medicine). Our innovative methodology is characterized by application of machine vision in the spectral range that allows imaging of subepidermally localized lesions, as in the case of cutaneous allergic reaction and the accompanying dermothermic effect (DTE). This technique also could be easily adopted for early automated detection of skin lesions with a high risk of neoplastic transformation, which significantly expands the capabilities of modern dermatoscopes.
SkinLogic™ Artificial Intelligence applied to our diagnostic systems represents a real breakthrough in the automated detection of skin pathology markers.The results of clinical trials conducted in 2018-19 at the Military Medical Institute under the direction of Prof. K. Jahnz-Rózyk showed the high diagnostic potential of the new method of assessing the results of allergic skin tests described by the AUC index, which reached almost 99%, and constitutes a very promising result on a global scale.